-- Days : -- HRS : -- MIN : -- SEC

Register Now →

News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

|Videos|February 9, 2022

INSPIRE and IMvigor011 Trials

Jason Starr, DO, discusses the INSPIRE and IMvigor011 studies that focused on the use of ctDNA in MRD.

Episodes in this series

EP. 1 Explaining Molecular Residual Disease

EP. 1 Explaining Molecular Residual Disease

EP. 2 The Evolution of Circulating Tumor DNA in Oncology

EP. 2 The Evolution of Circulating Tumor DNA in Oncology

EP. 3 MRD Assessments

EP. 3 MRD Assessments

EP. 4 MRD Results and Guiding Treatment Decisions

EP. 4 MRD Results and Guiding Treatment Decisions

EP. 5 MRD and Value-Based Care Models

EP. 5 MRD and Value-Based Care Models

EP. 6 Supporting MRD Availability

EP. 6 Supporting MRD Availability

EP. 7 INSPIRE and IMvigor011 Trials

EP. 7 INSPIRE and IMvigor011 Trials

EP. 8 Potential Changes for MRD in the Future

EP. 8 Potential Changes for MRD in the Future

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Yonatan S. Resnick, PharmD | Image: NECS

Considerations for Use of Tebentafusp, a BiTE Approved for Rare, High-Risk Uveal Melanoma

ByYonatan S. Resnick, PharmD

August 4th 2026

Richard Lafayette, MD | Image Credit: Stanford Medicine

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

ByBrooke McCormick,Richard Lafayette, MD, FACP

August 3rd 2026

Longer-Acting DME Drugs Ease Burden, Not Vision: John Kitchens, MD

ByLaura Joszt, MA,John Kitchens, MD

August 3rd 2026

Brittany Craiglow, MD in part 1 of an AJMC Q&A

The Psychiatric Burden of Pediatric Alopecia Areata: A Q&A With Brittany Craiglow, MD

BySkylar Jeremias,Brittany G. Craiglow, MD, FAAD

August 3rd 2026

Man clutching his stomach. | Image credit: @Shisuka_AdobeStock.jpeg

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

BySabrina McCrear

July 31st 2026

Trending on AJMC

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

FDA Panel Backs 6 Peptides for Compounding

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

Boston Panel Confronts Access and Coordination Gaps in Obesity Care

Pediatric Chronic Skin Disorders Linked to Poorer Mental Health